RecruitingNCT05809284
Determining the Mechanisms of Loss of CAR T Cell Persistence
Sponsor
University College, London
Enrollment
50 participants
Start Date
Oct 18, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.
Eligibility
Max Age: 25 Years
Inclusion Criteria2
- Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
- Written informed consent
Exclusion Criteria2
- Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
- Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05809284
Related Trials
Venetoclax Basket Trial for High Risk Hematologic Malignancies
NCT052926645 locations
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
NCT063430901 location
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT063168564 locations
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
NCT063260081 location
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NCT064812411 location